CAS No. : 927880-90-8

Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I005517
Molecular Formula:C₂₄H₁₆F₆N₆O
Molecular Weight:518.41
IC50:3-60 nM (B-Raf); 30 nM(EC50 for VEGFR2)
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.


Appearance:A crystalline solid
Cat No:I005517
Cas No:927880-90-8

RAF265 (CHIR-265) is a potent selective inhibitor of C-Raf/B-Raf/B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30 nM.

in vitro: RAF265 inhibits C-Raf, wild type B-Raf and mutant (V600E) B-Raf. RAF265 effectively block phosphorylation of Raf/'s downstream substrates MEK and ERK in cells and also kill melanoma and colorectal cancer cell lines harboring B-Raf mutations independent of PTEN mutation status. Raf kinase inhibition by RAF265 in mutant B-Raf melanoma cell lines causes cell cycle arrest and induces apoptosis, mimicking the effect of Raf RNAi in these cells. RAF265 also potently inhibits the phosphorylation of VEGFR2 and proliferation of VEGF-stimulated hMVEC [1]. In HT29 and MDAMB231 cells, RAF265 shows inhibitory activity with IC20 of 1 to 3 μM and IC50 of 5 to 10 μM, respectively. While RAF265 leads to a significant decrease in clonogenic survival in all tested cell lines, which means that RAF265 induces a dominant effect on clonogenic survival. Addition of RAF265 to RAD001 in HCT116 cells could lead to moderately decreased AKT, S6 protein, and 4EBP1 phosphorylation [2]. Raf265 markedly reduces the protein level of Bcl-2 and great inhibitory in CM- and NCI-H727 cells, while having no effect on the TRAIL susceptibility of BON1 and GOT1 cells [3].

in vivo: AF265 shows 71% to 72% TVI% (tumor volume inhibition percentage) in HCT116 xenografts at 12 mg/kg. While the combination of RAF265 and RAD001 shows enhanced antitumor activity with increased T10 (time to achieve a relative tumor volume of 10 times the initial tumor volume) and tumor growth delay. The combination of RAD001 and RAF265 also significantly enhances the activation of caspase-3 in HCT116 and MDAMB231 but not in A549 xenografts [2]. RAF265 inhibits FDG (2-deoxy-2-[18F]fluoro-d-glucose) accumulation and decreases the tumor volumes in A375M xenografts by orally dosed of 100 mg/kg [4].

[1]. AACR Meeting Abstracts 2008;2008:4876.

[2]. Mordant P, et al. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther, 2010, 9(2), 358-368.

[3]. Zitzmann K, et al. The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. Endocr Relat Cancer, 2011, 18(2), 277-285.

[4]. Tseng JR, et al. Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor. Neoplasia, 2011, 13(3), 266-275.

Related Products
  • CAS No. :883986-34-3
    Product Name:


    Cat No: I005309 View details
  • CAS No. :524722-52-9
    Product Name:

    Vandetanib hydrochloride

    Cat No: I003919 View details
  • CAS No. :515880-75-8
    Product Name:

    DMH 4

    Cat No: R057465 View details
  • CAS No. :849643-15-8
    Product Name:

    SU14813 maleate

    Cat No: I005095 View details